Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

161. Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials

Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials Ma D F, Qin, L Q, Wang P Y, Katoh R CRD summary This review (...) and serum bone-specific alkaline phosphatase (BAP) as a marker of bone formation. Included studies used either soy protein containing mainly isoflavones or isoflavone tablets. Isoflavone intake ranged from 37.3 to 118 mg/day and treatment duration from four to 48 weeks. Studies enrolled either Caucasian or Asian women who were not undergoing other osteoporosis therapy, and the majority enrolled post-menopausal women, with mean ages ranging from 51 to 62.4 years. All studies restricted common soy foods

2008 DARE.

162. Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women

Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women Mueller D, Gandjour A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women. Applied Health Economics and Health Policy 2008; 6(2-3): 113-135 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Absorptiometry, Photon /economics; Aged; Aged, 80 and over; Alendronate /economics /therapeutic use; Bone Density; Bone Density Conservation Agents /economics /therapeutic use; Bone and Bones /ultrasonography; Cost-Benefit Analysis; Female; Fractures, Bone /economics

2008 NHS Economic Evaluation Database.

163. Review: sparse good quality evidence supports the use of alternative therapies for menopausal symptoms

Review: sparse good quality evidence supports the use of alternative therapies for menopausal symptoms Review: sparse good quality evidence supports the use of alternative therapies for menopausal symptoms | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: sparse good quality evidence supports the use of alternative therapies for menopausal symptoms Article Text Treatment Review: sparse good quality evidence supports the use

2008 Evidence-Based Nursing

164. Exercise for vasomotor menopausal symptoms. Full Text available with Trip Pro

Exercise for vasomotor menopausal symptoms. Evidence suggests that a high proportion of perimenopausal and early postmenopausal women will experience some menopause symptoms, hot flushes being the most common. The effects caused by falling levels of estrogen may be alleviated by hormone replacement therapy (HRT) but there has been a marked global decline in the prescription and use of HRT due to concerns about the risks and benefits of HRT; consequently many women are now seeking alternatives (...) . As large numbers of women are choosing not to take HRT, it is increasingly important to identify evidence based lifestyle modifications, which can have a positive effect on menopausal symptoms.To examine the effectiveness of any type of exercise intervention in the management of vasomotor menopausal symptoms (hot flushes and night sweats) in perimenopausal and postmenopausal women.Searches of the following electronic bibliographic databases were performed to identify randomised controlled trials

2007 Cochrane

165. A randomized trial of alternative medicines for vasomotor symptoms of menopause. (Abstract)

A randomized trial of alternative medicines for vasomotor symptoms of menopause. 17179060 2007 01 09 2007 11 15 1539-3704 145 12 2006 Dec 19 Annals of internal medicine Ann. Intern. Med. A randomized trial of alternative medicines for vasomotor symptoms of menopause. 924-5 Mangione Carol M CM eng Comment Editorial United States Ann Intern Med 0372351 0003-4819 AIM IM Ann Intern Med. 2006 Dec 19;145(12):869-79 17179056 Female Hot Flashes drug therapy physiopathology Humans Menopause Middle Aged

2007 Annals of Internal Medicine Controlled trial quality: uncertain

166. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. Full Text available with Trip Pro

Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. The timing of initiation of hormone therapy may influence its effect on cardiovascular disease.To explore whether the effects of hormone therapy on risk of cardiovascular disease vary by age or years since menopause began.Secondary analysis of the Women's Health Initiative (WHI) randomized controlled trials of hormone therapy in which 10,739 postmenopausal women who had undergone a hysterectomy (...) were randomized to conjugated equine estrogens (CEE) or placebo and 16,608 postmenopausal women who had not had a hysterectomy were randomized to CEE plus medroxyprogesterone acetate (CEE + MPA) or placebo. Women aged 50 to 79 years were recruited to the study from 40 US clinical centers between September 1993 and October 1998.Statistical test for trend of the effect of hormone therapy on coronary heart disease (CHD) and stroke across categories of age and years since menopause in the combined

2007 JAMA Controlled trial quality: predicted high

167. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. Full Text available with Trip Pro

Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. To assess the long term risks and benefits of hormone replacement therapy (combined hormone therapy versus placebo, and oestrogen alone versus combined hormone therapy).Multicentre, randomised, placebo controlled, double blind trial.General practices in UK (384), Australia (91), and New Zealand (24 (...) revealed no significant differences.Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause. The results are consistent with the findings of the women's health initiative study and secondary prevention studies. Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different.Current Controlled Trials ISRCTN 63718836.

2007 BMJ Controlled trial quality: predicted high

168. Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis

Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

169. Effect of weighted exercises on bone mineral density in post menopausal women: a systematic review

Effect of weighted exercises on bone mineral density in post menopausal women: a systematic review Effect of weighted exercises on bone mineral density in post menopausal women: a systematic review Effect of weighted exercises on bone mineral density in post menopausal women: a systematic review Zehnacker C H, Bemis-Dougherty A CRD summary The review concluded that weighted exercises can be beneficial in maintaining bone mineral density (BMD) in postmenopausal women, and in increasing BMD (...) on bone mineral density in post menopausal women: a systematic review. Journal of Geriatric Physical Therapy 2007; 30(2): 79-88 PubMedID Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Aging /physiology; Bone Density; Exercise /physiology; Female; Humans; Osteoporosis, Postmenopausal /physiopathology /prevention & Postmenopause; control AccessionNumber 12007003006 Date bibliographic record published 14/02/2008 Date abstract record published 30/09/2008 Record Status

2007 DARE.

170. Trifolium pratense isoflavones in the treatment of menopausal hot flushes: a systematic review and meta-analysis

Trifolium pratense isoflavones in the treatment of menopausal hot flushes: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

171. Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole

Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women (...) , the incremental cost per QALY gained over TAM alone exceeded the EUR 30,000 threshold). The model was successfully validated. Authors' conclusions All three aromatase inhibitor (AI) strategies were cost-effective in comparison with tamoxifen (TAM) alone as adjuvant treatment of post-menopausal women with breast cancer (BC). Sequential TAM-AI was the preferred strategy among the three adjuvant hormonal treatments. CRD COMMENTARY - Selection of comparators The rationale for the choice of the comparators

2007 NHS Economic Evaluation Database.

172. Review: plant based oestrogens do not relieve hot flushes or other menopausal symptoms Full Text available with Trip Pro

Review: plant based oestrogens do not relieve hot flushes or other menopausal symptoms Review: plant based oestrogens do not relieve hot flushes or other menopausal symptoms | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: plant based oestrogens do not relieve hot flushes or other menopausal symptoms Article Text Treatment Review: plant based oestrogens do not relieve hot flushes or other menopausal symptoms Free Cathy R

2006 Evidence-Based Nursing

173. Recommendations for Aromatase inhibitors as adjuvant endocrine therapy for post-menopausal women with hormone receptor-positive early breast cancer

Recommendations for Aromatase inhibitors as adjuvant endocrine therapy for post-menopausal women with hormone receptor-positive early breast cancer Recommendations?for?Aromatase?inhibitors?as adjuvant?endocrine?therapy for?post-menopausal?women?with?hormone?receptor-positive?early?breast?cancer JULY?2006?| Incorporates?published?evidence?to?May?2005 A?CLINICAL?PRACTICE?GUIDELINE?DEVELOPED?BY?THE?NATIONAL?BREAST?CANCER?CENTRE* (NBCC*) This?document?supplements?guideline?recommendation?19?about (...) ?the?use?of?tamoxifen?for?the?management?of?post- menopausal?women?with?hormone?receptor-positive? early?breast?cancer?contained?in?the?NBCC*? Clinical?Practice Guidelines?for?the?Management?of?Early?Breast?Cancer , 2nd?edition,?2001?(page?9). 1 ISBN?Print:?1741270103?Online:?1741270111?CIP:?616.99449061 ©?Cancer?Australia?2011 *?In?February?2008,?National?Breast?Cancer?Centre?(NBCC),?incorporating?the?Ovarian?Cancer?Program,?changed its?name?to?National?Breast?and?Ovarian?Cancer?Centre?(NBOCC

2006 Cancer Australia

174. Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review Full Text available with Trip Pro

Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review Nedrow A, Miller J, Walker M, Nygren P, Huffman L H, Nelson H D CRD summary This review assessed randomised evidence for the use (...) of complementary and alternative therapies in the treatment of menopausal symptoms. The review included a wide range of interventions but concluded that there was insufficient evidence to demonstrate that any of the included therapies was effective. Given concerns about aspects of the review methods, it is not clear how reliable these conclusions are. Authors' objectives To evaluate the efficacy of complementary and alternative therapies for the management of menopausal symptoms. Searching MEDLINE, PsycINFO

2006 DARE.

175. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis

Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

176. Isoflavone therapy for menopausal flushes: a systematic review and meta-analysis

Isoflavone therapy for menopausal flushes: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

177. Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine insemination

Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine insemination Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine insemination Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine insemination Baysoy A, Serdaroglu H, Jamal H, Karatekeli E, Ozornek H, Attar E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of letrozole, one of a new class of drugs known as aromatase inhibitors, in women undergoing intrauterine insemination (IUI). This intervention was compared with the use of human menopausal gonadotrophin (HMG). Women undergoing ovarian stimulation and IUI, for whom no ovarian cyst was seen on the sonogram, were given

2006 NHS Economic Evaluation Database.

178. Menopausal hormone therapy (HT) in patients with breast cancer

Menopausal hormone therapy (HT) in patients with breast cancer Menopausal hormone therapy (HT) in patients with breast cancer Menopausal hormone therapy (HT) in patients with breast cancer Batur P, Blixen C E, Moore H C, Thacker H L, Xu M CRD summary This review examined the effects of menopausal hormone therapy on cancer reoccurrence, cancer mortality and overall mortality in patients with breast cancer. The authors concluded that hormone therapy is not associated with an increased incidence (...) of these outcomes. However, the reliability of this conclusion is limited by combining the results from studies of varying design. Authors' objectives To assess the effect of menopausal hormone therapy (HT) on cancer reoccurrence, cancer-related mortality and overall mortality in patients with a diagnosis of breast cancer. Searching MEDLINE, CINAHL and HealthSTAR were searched from 1967 to 2001; the search terms were given. In addition, existing reviews were used to identify references and conference

2006 DARE.

179. The menopausal transition increases the risk of depressive symptoms and depression diagnosis in women without a history of depression

The menopausal transition increases the risk of depressive symptoms and depression diagnosis in women without a history of depression The menopausal transition increases the risk of depressive symptoms and depression diagnosis in women without a history of depression | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please (...) see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The menopausal transition increases the risk of depressive symptoms and depression diagnosis in women without a history

2006 Evidence-Based Mental Health

180. Entering menopause increases the risk of first episode depression

Entering menopause increases the risk of first episode depression Entering menopause increases the risk of first episode depression | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Entering menopause increases the risk of first episode depression Article Text Aetiology Entering menopause increases the risk of first episode depression Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article

2006 Evidence-Based Mental Health